Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 186

1.

Clinical Activity, Tolerability, and Long-term Follow-up of Durvalumab in Patients With Advanced NSCLC.

Antonia SJ, Balmanoukian A, Brahmer J, Ou SI, Hellmann MD, Kim SW, Ahn MJ, Kim DW, Gutierrez M, Liu SV, Schöffski P, Jäger D, Jamal R, Jerusalem G, Lutzky J, Nemunaitis J, Calabro L, Weiss J, Gadgeel S, Bhosle J, Ascierto PA, Rebelatto MC, Narwal R, Liang M, Xiao F, Antal J, Abdullah S, Angra N, Gupta AK, Khleif SN, Segal NH.

J Thorac Oncol. 2019 Jun 19. pii: S1556-0864(19)30475-7. doi: 10.1016/j.jtho.2019.06.010. [Epub ahead of print]

2.

HER2+ breast cancer treatment and cardiotoxicity: monitoring and management.

Jerusalem G, Lancellotti P, Kim SB.

Breast Cancer Res Treat. 2019 Jun 5. doi: 10.1007/s10549-019-05303-y. [Epub ahead of print] Review.

PMID:
31165940
3.

Health related quality of life in older patients with solid tumors and prognostic factors for decline.

Decoster L, Quinten C, Kenis C, Flamaing J, Debruyne PR, De Groof I, Focan C, Cornelis F, Verschaeve V, Bachmann C, Bron D, Luce S, Debugne G, den Bulck, Goeminne JC, Baitar A, Geboers K, Petit B, Langenaeken C, Van Rijswijk R, Specenier P, Jerusalem G, Praet JP, Vandenborre K, Lobelle JP, Lycke M, Milisen K, Wildiers H.

J Geriatr Oncol. 2019 Apr 17. pii: S1879-4068(18)30373-4. doi: 10.1016/j.jgo.2019.03.018. [Epub ahead of print]

PMID:
31005649
4.

Pharmacokinetic and exploratory exposure-response analysis of pertuzumab in patients with operable HER2-positive early breast cancer in the APHINITY study.

Kirschbrown WP, Kågedal M, Wang B, Lindbom L, Knott A, Mack R, Monemi S, Nijem I, Girish S, Freeman C, Fumagalli D, McConnell R, Jerusalem G, Twelves C, Baselga J, von Minckwitz G, Bines J, Garg A.

Cancer Chemother Pharmacol. 2019 Jun;83(6):1147-1158. doi: 10.1007/s00280-019-03826-1. Epub 2019 Apr 11.

5.

Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial.

Ribi K, Luo W, Colleoni M, Karlsson P, Chirgwin J, Aebi S, Jerusalem G, Neven P, Di Lauro V, Gomez HL, Ruhstaller T, Abdi E, Biganzoli L, Müller B, Barbeaux A, Graas MP, Rabaglio M, Francis PA, Foukakis T, Pagani O, Graiff C, Vorobiof D, Maibach R, Di Leo A, Gelber RD, Goldhirsch A, Coates AS, Regan MM, Bernhard J; SOLE Investigators.

Br J Cancer. 2019 May;120(10):959-967. doi: 10.1038/s41416-019-0435-4. Epub 2019 Apr 10.

PMID:
30967649
6.

Pharmacokinetics and Safety of Olaparib in Patients with Advanced Solid Tumours and Renal Impairment.

Rolfo C, de Vos-Geelen J, Isambert N, Molife LR, Schellens JHM, De Grève J, Dirix L, Grundtvig-Sørensen P, Jerusalem G, Leunen K, Mau-Sørensen M, Plummer R, Learoyd M, Bannister W, Fielding A, Ravaud A.

Clin Pharmacokinet. 2019 Mar 16. doi: 10.1007/s40262-019-00754-4. [Epub ahead of print]

PMID:
30877569
7.

Atypical patterns of response to immune checkpoint inhibitors: interpreting pseudoprogression and hyperprogression in decision making for patients' treatment.

Onesti CE, Frères P, Jerusalem G.

J Thorac Dis. 2019 Jan;11(1):35-38. doi: 10.21037/jtd.2018.12.47. No abstract available.

8.

Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial.

Loi S, Giobbie-Hurder A, Gombos A, Bachelot T, Hui R, Curigliano G, Campone M, Biganzoli L, Bonnefoi H, Jerusalem G, Bartsch R, Rabaglio-Poretti M, Kammler R, Maibach R, Smyth MJ, Di Leo A, Colleoni M, Viale G, Regan MM, André F; International Breast Cancer Study Group and the Breast International Group.

Lancet Oncol. 2019 Mar;20(3):371-382. doi: 10.1016/S1470-2045(18)30812-X. Epub 2019 Feb 11.

PMID:
30765258
9.

Neutropenia management in patients receiving myelosuppressive polychemotherapy for early breast cancer in Belgium: BRONS study results.

Catala G, Mebis J, Jerusalem G, Verhoeven D, Awada A, Bols A, Somers L, Van Den Broeck A, Duhoux FP, Machiels JP.

Acta Clin Belg. 2019 Jan 4:1-8. doi: 10.1080/17843286.2018.1563735. [Epub ahead of print]

PMID:
30609907
10.

Expression of MT4-MMP, EGFR, and RB in Triple-Negative Breast Cancer Strongly Sensitizes Tumors to Erlotinib and Palbociclib Combination Therapy.

Foidart P, Yip C, Radermacher J, Blacher S, Lienard M, Montero-Ruiz L, Maquoi E, Montaudon E, Château-Joubert S, Collignon J, Coibion M, Jossa V, Marangoni E, Noël A, Sounni NE, Jerusalem G.

Clin Cancer Res. 2019 Mar 15;25(6):1838-1850. doi: 10.1158/1078-0432.CCR-18-1880. Epub 2018 Nov 30.

PMID:
30504427
11.

Determining clinically important differences in health-related quality of life in older patients with cancer undergoing chemotherapy or surgery.

Quinten C, Kenis C, Decoster L, Debruyne PR, De Groof I, Focan C, Cornelis F, Verschaeve V, Bachmann C, Bron D, Luce S, Debugne G, Van den Bulck H, Goeminne JC, Baitar A, Geboers K, Petit B, Langenaeken C, Van Rijswijk R, Specenier P, Jerusalem G, Praet JP, Vandenborre K, Lycke M, Flamaing J, Milisen K, Lobelle JP, Wildiers H.

Qual Life Res. 2019 Mar;28(3):663-676. doi: 10.1007/s11136-018-2062-6. Epub 2018 Dec 3.

PMID:
30511255
12.

Randomized controlled trial of an 8-week intervention combining self-care and hypnosis for post-treatment cancer patients: study protocol.

Grégoire C, Faymonville ME, Vanhaudenhuyse A, Charland-Verville V, Jerusalem G, Bragard I.

BMC Cancer. 2018 Nov 15;18(1):1113. doi: 10.1186/s12885-018-5046-6.

13.

Phase 1b Study of Trebananib Plus Paclitaxel and Trastuzumab in Patients With HER2-Positive Locally Recurrent or Metastatic Breast Cancer.

Kaufman PA, Wildiers H, Freyer G, Kemeny M, Gonçalves A, Jerusalem G, Stopeck A, Vrindavanam N, Dalenc F, Nanayakkara N, Wu B, Pickett CA.

Clin Breast Cancer. 2019 Feb;19(1):47-57. doi: 10.1016/j.clbc.2018.09.012. Epub 2018 Oct 9.

PMID:
30420181
14.

Pharmacokinetic Effects and Safety of Olaparib Administered with Endocrine Therapy: A Phase I Study in Patients with Advanced Solid Tumours.

Plummer R, Verheul HM, De Vos FYFL, Leunen K, Molife LR, Rolfo C, Grundtvig-Sørensen P, De Grève J, Rottey S, Jerusalem G, Italiano A, Spicer J, Dirix L, Goessl C, Birkett J, Spencer S, Learoyd M, Bailey C, Dean E.

Adv Ther. 2018 Nov;35(11):1945-1964. doi: 10.1007/s12325-018-0804-z. Epub 2018 Oct 15.

PMID:
30324586
15.

Predictive and prognostic role of peripheral blood eosinophil count in triple-negative and hormone receptor-negative/HER2-positive breast cancer patients undergoing neoadjuvant treatment.

Onesti CE, Josse C, Poncin A, Frères P, Poulet C, Bours V, Jerusalem G.

Oncotarget. 2018 Sep 14;9(72):33719-33733. doi: 10.18632/oncotarget.26120. eCollection 2018 Sep 14.

16.

Real-world use of granulocyte colony-stimulating factor in ambulatory breast cancer patients: a cross-sectional study.

Van Ryckeghem F, Haverbeke C, Wynendaele W, Jerusalem G, Somers L, Van den Broeck A, Vingerhoedt S, Van Belle S.

Support Care Cancer. 2019 Mar;27(3):1099-1108. doi: 10.1007/s00520-018-4399-3. Epub 2018 Aug 11.

PMID:
30099601
17.

Cardio-Oncology Services: rationale, organization, and implementation.

Lancellotti P, Suter TM, López-Fernández T, Galderisi M, Lyon AR, Van der Meer P, Cohen Solal A, Zamorano JL, Jerusalem G, Moonen M, Aboyans V, Bax JJ, Asteggiano R.

Eur Heart J. 2019 Jun 7;40(22):1756-1763. doi: 10.1093/eurheartj/ehy453.

18.

Codon-specific translation reprogramming promotes resistance to targeted therapy.

Rapino F, Delaunay S, Rambow F, Zhou Z, Tharun L, De Tullio P, Sin O, Shostak K, Schmitz S, Piepers J, Ghesquière B, Karim L, Charloteaux B, Jamart D, Florin A, Lambert C, Rorive A, Jerusalem G, Leucci E, Dewaele M, Vooijs M, Leidel SA, Georges M, Voz M, Peers B, Büttner R, Marine JC, Chariot A, Close P.

Nature. 2018 Jun;558(7711):605-609. doi: 10.1038/s41586-018-0243-7. Epub 2018 Jun 20.

PMID:
29925953
19.

Adherence to geriatric assessment-based recommendations in older patients with cancer: a multicenter prospective cohort study in Belgium.

Kenis C, Decoster L, Flamaing J, Debruyne PR, De Groof I, Focan C, Cornélis F, Verschaeve V, Bachmann C, Bron D, Luce S, Debugne G, Van den Bulck H, Goeminne JC, Schrijvers D, Geboers K, Petit B, Langenaeken C, Van Rijswijk R, Specenier P, Jerusalem G, Praet JP, Vandenborre K, Lobelle JP, Lycke M, Milisen K, Wildiers H.

Ann Oncol. 2018 Sep 1;29(9):1987-1994. doi: 10.1093/annonc/mdy210.

PMID:
29905766
20.

Exercise and Education Program After Breast Cancer: Benefits on Quality of Life and Symptoms at 3, 6, 12, and 24 Months' Follow-up.

Leclerc AF, Slomian J, Jerusalem G, Coucke P, Bury T, Deflandre D, Devos M, Bruyère O, Foidart-Dessalle M, Kaux JF, Crielaard JM, Maquet D.

Clin Breast Cancer. 2018 Oct;18(5):e1189-e1204. doi: 10.1016/j.clbc.2018.05.004. Epub 2018 May 19.

PMID:
29880408
21.

Everolimus Plus Exemestane vs Everolimus or Capecitabine Monotherapy for Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer: The BOLERO-6 Randomized Clinical Trial.

Jerusalem G, de Boer RH, Hurvitz S, Yardley DA, Kovalenko E, Ejlertsen B, Blau S, Özgüroglu M, Landherr L, Ewertz M, Taran T, Fan J, Noel-Baron F, Louveau AL, Burris H.

JAMA Oncol. 2018 Oct 1;4(10):1367-1374. doi: 10.1001/jamaoncol.2018.2262.

22.

Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3.

Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im SA, Petrakova K, Bianchi GV, Esteva FJ, Martín M, Nusch A, Sonke GS, De la Cruz-Merino L, Beck JT, Pivot X, Vidam G, Wang Y, Rodriguez Lorenc K, Miller M, Taran T, Jerusalem G.

J Clin Oncol. 2018 Aug 20;36(24):2465-2472. doi: 10.1200/JCO.2018.78.9909. Epub 2018 Jun 3.

PMID:
29860922
23.

Variations of circulating cardiac biomarkers during and after anthracycline-containing chemotherapy in breast cancer patients.

Frères P, Bouznad N, Servais L, Josse C, Wenric S, Poncin A, Thiry J, Moonen M, Oury C, Lancellotti P, Bours V, Jerusalem G.

BMC Cancer. 2018 Jan 29;18(1):102. doi: 10.1186/s12885-018-4015-4.

24.

First-line vs second-line fulvestrant for hormone receptor-positive advanced breast cancer: A post-hoc analysis of the CONFIRM study.

Di Leo A, Jerusalem G, Torres R, Verhoeven D, Pendergrass K, Malorni L, Lichfield J, Martin M.

Breast. 2018 Apr;38:144-149. doi: 10.1016/j.breast.2017.12.016. Epub 2018 Jan 8.

PMID:
29324303
25.

Natural Antisense Transcripts: Molecular Mechanisms and Implications in Breast Cancers.

Latgé G, Poulet C, Bours V, Josse C, Jerusalem G.

Int J Mol Sci. 2018 Jan 2;19(1). pii: E123. doi: 10.3390/ijms19010123. Review.

26.

Transcriptome-wide analysis of natural antisense transcripts shows their potential role in breast cancer.

Wenric S, ElGuendi S, Caberg JH, Bezzaou W, Fasquelle C, Charloteaux B, Karim L, Hennuy B, Frères P, Collignon J, Boukerroucha M, Schroeder H, Olivier F, Jossa V, Jerusalem G, Josse C, Bours V.

Sci Rep. 2017 Dec 12;7(1):17452. doi: 10.1038/s41598-017-17811-2.

27.

A randomized phase II study evaluating different maintenance schedules of nab-paclitaxel in the first-line treatment of metastatic breast cancer: final results of the IBCSG 42-12/BIG 2-12 SNAP trial.

Gennari A, Sun Z, Hasler-Strub U, Colleoni M, Kennedy MJ, Von Moos R, Cortés J, Vidal MJ, Hennessy B, Walshe J, Parraga KA, Ribi K, Bernhard J, Murillo SM, Pagani O, Barbeaux A, Borstnar S, Rabaglio-Poretti M, Maibach R, Regan MM, Jerusalem G; International Breast Cancer Study Group, Cancer Trials Ireland and SOLTI Group.

Ann Oncol. 2018 Mar 1;29(3):661-668. doi: 10.1093/annonc/mdx772.

PMID:
29228091
28.

Phase II study of buparlisib (BKM120) and trastuzumab in patients with HER2+ locally advanced or metastatic breast cancer resistant to trastuzumab-based therapy.

Pistilli B, Pluard T, Urruticoechea A, Farci D, Kong A, Bachelot T, Chan S, Han HS, Jerusalem G, Urban P, Robinson D, Mouhaër SL, Tomaso ED, Massacesi C, Saura C.

Breast Cancer Res Treat. 2018 Apr;168(2):357-364. doi: 10.1007/s10549-017-4596-7. Epub 2017 Dec 2.

PMID:
29198055
29.

Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial.

Colleoni M, Luo W, Karlsson P, Chirgwin J, Aebi S, Jerusalem G, Neven P, Hitre E, Graas MP, Simoncini E, Kamby C, Thompson A, Loibl S, Gavilá J, Kuroi K, Marth C, Müller B, O'Reilly S, Di Lauro V, Gombos A, Ruhstaller T, Burstein H, Ribi K, Bernhard J, Viale G, Maibach R, Rabaglio-Poretti M, Gelber RD, Coates AS, Di Leo A, Regan MM, Goldhirsch A; SOLE Investigators.

Lancet Oncol. 2018 Jan;19(1):127-138. doi: 10.1016/S1470-2045(17)30715-5. Epub 2017 Nov 17.

PMID:
29158011
30.

Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study.

Dirix LY, Takacs I, Jerusalem G, Nikolinakos P, Arkenau HT, Forero-Torres A, Boccia R, Lippman ME, Somer R, Smakal M, Emens LA, Hrinczenko B, Edenfield W, Gurtler J, von Heydebreck A, Grote HJ, Chin K, Hamilton EP.

Breast Cancer Res Treat. 2018 Feb;167(3):671-686. doi: 10.1007/s10549-017-4537-5. Epub 2017 Oct 23.

31.

Communication of healthcare professionals: Is there ageism?

Schroyen S, Adam S, Marquet M, Jerusalem G, Thiel S, Giraudet AL, Missotten P.

Eur J Cancer Care (Engl). 2018 Jan;27(1). doi: 10.1111/ecc.12780. Epub 2017 Sep 27.

PMID:
28960583
32.

Group interventions to reduce emotional distress and fatigue in breast cancer patients: a 9-month follow-up pragmatic trial.

Grégoire C, Bragard I, Jerusalem G, Etienne AM, Coucke P, Dupuis G, Lanctôt D, Faymonville ME.

Br J Cancer. 2017 Nov 7;117(10):1442-1449. doi: 10.1038/bjc.2017.326. Epub 2017 Sep 19.

33.

Association between self-perception of aging, view of cancer and health of older patients in oncology: a one-year longitudinal study.

Schroyen S, Missotten P, Jerusalem G, Van den Akker M, Buntinx F, Adam S.

BMC Cancer. 2017 Sep 2;17(1):614. doi: 10.1186/s12885-017-3607-8.

34.

Protocol update and preliminary results of EACVI/HFA Cardiac Oncology Toxicity (COT) Registry of the European Society of Cardiology.

Lancellotti P, Galderisi M, Donal E, Edvardsen T, Popescu BA, Farmakis D, Filippatos G, Habib G, Lestuzzi C, Santoro C, Moonen M, Jerusalem G, Andarala M, Anker SD; ESC Cardiac Oncology Toxicity Long-Term Registry Investigators.

ESC Heart Fail. 2017 Aug;4(3):312-318. doi: 10.1002/ehf2.12162. Epub 2017 May 2.

35.

[Carcinoma of unknown primary : a not so rare entity].

Gonne E, Collignon J, Jerusalem G, Gennigens C.

Rev Med Liege. 2016 Oct;71(10):449-454. Review. French.

36.

[Cancer therapy-induced cardiotoxicity].

Frères P, Poncin A, Moonen M, Josse C, Oury C, Bours V, Lancellotti P, Jerusalem G.

Rev Med Liege. 2016 Sep;71(9):382-387. Review. French.

37.

Multidisciplinary rehabilitation program after breast cancer: benefits on physical function, anthropometry and quality of life.

Leclerc AF, Foidart-Dessalle M, Tomasella M, Coucke P, Devos M, Bruyère O, Bury T, Deflandre D, Jerusalem G, Lifrange E, Kaux JF, Crielaard JM, Maquet D.

Eur J Phys Rehabil Med. 2017 Oct;53(5):633-642. doi: 10.23736/S1973-9087.17.04551-8. Epub 2017 Mar 20.

38.

A Nonrandomized Comparison Study of Self-Hypnosis, Yoga, and Cognitive-Behavioral Therapy to Reduce Emotional Distress in Breast Cancer Patients.

Bragard I, Etienne AM, Faymonville ME, Coucke P, Lifrange E, Schroeder H, Wagener A, Dupuis G, Jerusalem G.

Int J Clin Exp Hypn. 2017 Apr-Jun;65(2):189-209. doi: 10.1080/00207144.2017.1276363.

PMID:
28230462
39.

Relationship between Pulmonary Adverse Events and Everolimus Exposure in Japanese and Non-Japanese Patients: A Meta-Analysis of Oncology Trials.

Noguchi S, Shinohara N, Ito T, Ohtsu A, Ravaud A, Jerusalem G, Ohno N, Gallo J, Bouillaud E, Fan J, Nonomura N.

Oncology. 2017;92(5):243-254. doi: 10.1159/000457904. Epub 2017 Feb 21.

PMID:
28219073
40.

MT4-MMP and EGFR expression levels are key biomarkers for breast cancer patient response to chemotherapy and erlotinib.

Yip C, Foidart P, Somja J, Truong A, Lienard M, Feyereisen E, Schroeder H, Gofflot S, Donneau AF, Collignon J, Delvenne P, Sounni NE, Jerusalem G, Noël A.

Br J Cancer. 2017 Mar 14;116(6):742-751. doi: 10.1038/bjc.2017.23. Epub 2017 Feb 14.

41.

Safety, Efficacy, and Patient Acceptability of Everolimus in the Treatment of Breast Cancer.

Lousberg L, Jerusalem G.

Breast Cancer (Auckl). 2017 Jan 4;10:239-252. doi: 10.4137/BCBCR.S12443. eCollection 2016. Review.

42.

Multidisciplinary management of breast cancer.

Leclerc AF, Jerusalem G, Devos M, Crielaard JM, Maquet D.

Arch Public Health. 2016 Dec 5;74:50. eCollection 2016.

43.
44.

Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-label Studies.

Dirix L, Swaisland H, Verheul HM, Rottey S, Leunen K, Jerusalem G, Rolfo C, Nielsen D, Molife LR, Kristeleit R, Vos-Geelen J, Mau-Sørensen M, Soetekouw P, van Herpen C, Fielding A, So K, Bannister W, Plummer R.

Clin Ther. 2016 Oct;38(10):2286-2299. doi: 10.1016/j.clinthera.2016.08.010. Epub 2016 Oct 10.

PMID:
27745744
45.

The link between self-perceptions of aging, cancer view and physical and mental health of older people with cancer: A cross-sectional study.

Schroyen S, Marquet M, Jerusalem G, Dardenne B, Van den Akker M, Buntinx F, Adam S, Missotten P.

J Geriatr Oncol. 2017 Jan;8(1):64-68. doi: 10.1016/j.jgo.2016.09.001. Epub 2016 Sep 19.

PMID:
27659547
46.

Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: primary results of a phase IIIb, open-label, single-arm, expanded-access multicenter trial (BALLET).

Jerusalem G, Mariani G, Ciruelos EM, Martin M, Tjan-Heijnen VC, Neven P, Gavila JG, Michelotti A, Montemurro F, Generali D, Simoncini E, Lang I, Mardiak J, Naume B, Camozzi M, Lorizzo K, Bianchetti S, Conte P.

Ann Oncol. 2016 Sep;27(9):1719-25. doi: 10.1093/annonc/mdw249. Epub 2016 Jun 29.

PMID:
27358383
47.

Triple-negative breast cancer: treatment challenges and solutions.

Collignon J, Lousberg L, Schroeder H, Jerusalem G.

Breast Cancer (Dove Med Press). 2016 May 20;8:93-107. doi: 10.2147/BCTT.S69488. eCollection 2016.

48.

Tissue Factor Induced by Epithelial-Mesenchymal Transition Triggers a Procoagulant State That Drives Metastasis of Circulating Tumor Cells.

Bourcy M, Suarez-Carmona M, Lambert J, Francart ME, Schroeder H, Delierneux C, Skrypek N, Thompson EW, Jérusalem G, Berx G, Thiry M, Blacher S, Hollier BG, Noël A, Oury C, Polette M, Gilles C.

Cancer Res. 2016 Jul 15;76(14):4270-82. doi: 10.1158/0008-5472.CAN-15-2263. Epub 2016 May 24.

49.

Predicting Reversibility of Anticancer Drugs-Related Cardiac Dysfunction: A New Piece to the Routine Use of Deformation Imaging.

Lancellotti P, Moonen M, Jerusalem G.

Echocardiography. 2016 Apr;33(4):504-9. doi: 10.1111/echo.13187. No abstract available.

PMID:
27103482
50.

Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3.

André F, Hurvitz S, Fasolo A, Tseng LM, Jerusalem G, Wilks S, O'Regan R, Isaacs C, Toi M, Burris H, He W, Robinson D, Riester M, Taran T, Chen D, Slamon D.

J Clin Oncol. 2016 Jun 20;34(18):2115-24. doi: 10.1200/JCO.2015.63.9161. Epub 2016 Apr 18. Erratum in: J Clin Oncol. 2019 Feb 1;37(4):357.

PMID:
27091708

Supplemental Content

Loading ...
Support Center